Albany Molecular Research Inc. Opens New Facilities in Singapore And India

ALBANY, N.Y.--(BUSINESS WIRE)--Nov. 1, 2005--Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced that its wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte. Ltd. (AMRSRC), has moved into permanent laboratory facilities in Singapore that provide room for significant growth. Earlier this year, the company established AMRSRC in temporary facilities while the new laboratories were under construction. New facilities are now also operational in Hyderabad, India. In Singapore, AMRI's new state-of-the-art 16,000 square foot facility is located in Science Park III, near the Biopolis, a major biomedical research hub. The facility can currently accommodate over 50 scientists. Capabilities there include medicinal chemistry support, custom synthesis of building blocks and scaffolds, as well as non-GMP scale up. AMRI has an additional 29,000 square feet of space in Singapore at this facility and currently plans to add laboratories for cGMP synthesis and analytical chemistry, as well as additional facilities for chemical synthesis. The company also announced that it has opened its first laboratory in India. Albany Molecular Research Hyderabad Research Centre, Pvt. Ltd. (AMRHRC), a wholly owned subsidiary of the company, is located in the ICICI Knowledge Park near Hyderabad. The newly constructed laboratory holds up to 12 scientists and is being used for custom synthesis of scaffolds and building blocks, as well as preparation of reference standards. A second laboratory for preparing up to kilogram quantities of pharmaceutical intermediates, starting materials and other compounds is currently under construction and expected to be operational by early next year. Together, the two laboratories in India are anticipated to accommodate up to 30 scientists.

Back to news